Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Nektar Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026. Open the filing →
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
FAQ
- What is Nektar Therapeutics's EBIT?
- Nektar Therapeutics (NKTR) reported EBIT of -$39.05M in Q1 2026.
- How has Nektar Therapeutics's EBIT changed year-over-year?
- Nektar Therapeutics's EBIT increased by 12.3% year-over-year, from -$44.54M to -$39.05M.
- What is the long-term trend for Nektar Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Nektar Therapeutics's EBIT has grown at a -25.1% compound annual growth rate (CAGR), from -$446.1M to -$140.1M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Nektar Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude